Prospects for Redifferentiating Agents in the Use of Radioactive Iodine Therapy for Thyroid Cancer.
作者信息
Jhiang Sissy M, Konda Bhavana, Sipos Jennifer A, Nabhan Fadi A
机构信息
Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio.
Division of Endocrinology and Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
出版信息
Thyroid. 2020 Apr;30(4):471-473. doi: 10.1089/thy.2020.0143. Epub 2020 Mar 26.
Abstract
摘要
相似文献
1
Prospects for Redifferentiating Agents in the Use of Radioactive Iodine Therapy for Thyroid Cancer.放射性碘疗法治疗甲状腺癌中再分化剂的应用前景
Thyroid. 2020 Apr;30(4):471-473. doi: 10.1089/thy.2020.0143. Epub 2020 Mar 26.
2
Redifferentiating agents in non-radioiodine avid cancer.非放射性碘摄取性癌症中的再分化剂
Q J Nucl Med Mol Imaging. 2009 Oct;53(5):513-9.
3
Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update.放射性碘治疗分化型甲状腺癌：2020 年更新。
AJR Am J Roentgenol. 2020 Aug;215(2):285-291. doi: 10.2214/AJR.19.22626. Epub 2020 Jun 17.
4
[Treatment of thyroid cancer with radioactive iodine: indication and practice].
Nihon Jibiinkoka Gakkai Kaiho. 2012 Mar;115(3):204-5, 208. doi: 10.3950/jibiinkoka.115.204.
5
Definition and management of radioactive iodine-refractory differentiated thyroid cancer.放射性碘难治性分化型甲状腺癌的定义与管理
Lancet Diabetes Endocrinol. 2014 May;2(5):356-8. doi: 10.1016/S2213-8587(13)70215-8. Epub 2014 Jan 30.
6
Should radioactive iodine therapy be administrated in patient of papillary thyroid carcinoma?甲状腺乳头状癌患者是否应进行放射性碘治疗？
Chin Med J (Engl). 2014;127(16):3039-40.
7
The use of radioactive iodine in patients with papillary and follicular thyroid cancer.放射性碘在乳头状和滤泡状甲状腺癌患者中的应用。
J Clin Endocrinol Metab. 1998 Dec;83(12):4195-203. doi: 10.1210/jcem.83.12.5293-1.
8
Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine.低碘饮食在放射性碘治疗分化型甲状腺癌中的应用
Endocrine. 2002 Mar;17(2):141-3. doi: 10.1385/ENDO:17:2:141.
9
The role of radiotherapy and radioactive iodine in the treatment of thyroid cancer without metastases.放射治疗和放射性碘在无转移甲状腺癌治疗中的作用。
Ann Radiol (Paris). 1977 Nov-Dec;20(8):801-9.
10
Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer.放射性碘在低危和中危甲状腺乳头状癌患者中的应用。
Future Oncol. 2013 Jul;9(7):921-3. doi: 10.2217/fon.13.80.
引用本文的文献
1
Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.新型甲状腺癌抑制剂治疗方法的研究进展。
Int J Mol Sci. 2021 Oct 31;22(21):11829. doi: 10.3390/ijms222111829.
2
Advances in Functional Imaging of Differentiated Thyroid Cancer.分化型甲状腺癌的功能成像进展
Cancers (Basel). 2021 Sep 23;13(19):4748. doi: 10.3390/cancers13194748.
3
Personalized radioiodine therapy for thyroid cancer patients with known disease.针对已知病情的甲状腺癌患者的个性化放射性碘治疗。
Fac Rev. 2021 Apr 7;10:36. doi: 10.12703/r/10-36. eCollection 2021.
本文引用的文献
1
Molecular therapeutics for anaplastic thyroid cancer.间变性甲状腺癌的分子治疗。
Semin Cancer Biol. 2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25.
2
A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.一种新型的酪氨酸激酶抑制剂可通过上调间变性甲状腺癌的内源性钠/碘转运体表达来增强放射性碘摄取。
Thyroid. 2020 Apr;30(4):501-518. doi: 10.1089/thy.2018.0626. Epub 2020 Feb 14.
3
Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.靶向新型钠碘转运体相互作用蛋白 ADP-核糖基化因子 4 和含缬氨酸蛋白增强放射性碘摄取。
Cancer Res. 2020 Jan 1;80(1):102-115. doi: 10.1158/0008-5472.CAN-19-1957. Epub 2019 Oct 31.
4
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.丝裂原活化蛋白激酶通路抑制在放射性碘难治性分化型甲状腺癌再分化中的应用：一项不断发展的方案。
Thyroid. 2019 Nov;29(11):1634-1645. doi: 10.1089/thy.2019.0143.
5
I Positron Emission Tomography/Computed Tomography Versus Conventional Radioiodine Imaging in Differentiated Thyroid Cancer: A Review.正电子发射断层扫描/计算机断层扫描与分化型甲状腺癌的常规放射性碘成像：综述。
Thyroid. 2019 Nov;29(11):1523-1535. doi: 10.1089/thy.2018.0598. Epub 2019 Sep 27.
6
Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair.抑制BRAF癌基因介导的放射抗性通过限制DNA双链断裂修复有效地使BRAF突变的甲状腺癌细胞对辐射敏感。
Clin Cancer Res. 2019 Aug 1;25(15):4749-4760. doi: 10.1158/1078-0432.CCR-18-3625. Epub 2019 May 16.
7
Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.联合抑制MEK和Pi3'-激酶在体外和体内对甲状腺癌的靶向治疗中显示出协同作用。
Oncotarget. 2017 Apr 11;8(15):24604-24620. doi: 10.18632/oncotarget.15599.
8
Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin.肿瘤学在研抑制剂和芹菜素对甲状腺放射性碘摄取的调节作用
Oncotarget. 2015 Oct 13;6(31):31792-804. doi: 10.18632/oncotarget.5172.
9
Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.达拉非尼治疗碘难治性 BRAF V600E 突变转移性甲状腺乳头状癌的再分化作用。
Clin Cancer Res. 2015 Mar 1;21(5):1028-35. doi: 10.1158/1078-0432.CCR-14-2915. Epub 2014 Dec 30.
10
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.索拉非尼增强晚期甲状腺癌的放射性碘摄取。
N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.
Zotero 插件